Neither CJC-1295 (No DAC) nor Ipamorelin is an approved medicine in Australia - neither is on the Australian Register of Therapeutic Goods, and the TGA has not evaluated either for safety, quality or effectiveness
Researchers and physicians, like myself, are exploring new ways to use this substance
Concentration(s) Common formulations:- **PT-141 Injectable:** 10 mg/mL reconstituted solution- **Sermorelin Injectable:** 3 mg/mL, 6 mg/mL, 9 mg/mL- **GHK-Cu Topical:** 0.1% 3%- **NAD+ Injectable:** 100 mg/mL 500 mg/mL- **Oral Troche (PT-141, Sermorelin, NAD+):** 0.5-2 mg per dose Maximum Dosage (Day, Wk) Recommended maximum doses:- **PT-141:** 1.75 mg subcutaneous per dose, max 2 doses per week- **Sermorelin:** 200-500 mcg subcutaneous per dose, daily- **GHK-Cu:** Apply 1-2 times daily- **NAD+:** 50-500 mg subcutaneous per dose, 1-3x per week Contraindications Pregnancy, breastfeeding, active cancer, history of pituitary tumors, cardiovascular disease (for PT-141), history of melanoma (for GHK-Cu), uncontrolled hypertension, or hypersensitivity to any of the compounds
A guide cannula (62004, RWD Life Science) and a bipolar electrode were vertically implanted into the hippocampal CA1 subregion (AP 2.0 mm